Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.34 |
| ▸ | GSK3A | P49840 | 2/20 | 0.34 |
| ▸ | MAT2A | P31153 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.32 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.31 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15598610 | 1.00 | GSK3B (0.34) | GSK3BGSK3AMAT2AALDH1A1GAA | |
| SCHEMBL15598613 | 1.00 | GSK3B (0.34) | GSK3BGSK3AMAT2AALDH1A1GAA | |
| SCHEMBL15598612 | 0.90 | KDM4E (0.39) | GSK3BGSK3AMAT2AALDH1A1GAA | |
| SCHEMBL15558529 | 0.87 | COMT (0.36) | GSK3BGSK3AMAT2AALDH1A1GAA | |
| SCHEMBL15559495 | 0.81 | ALDH1A1 (0.39) | GSK3BGSK3AMAT2AALDH1A1NPC1 | |
| SCHEMBL15559028 | 0.81 | GSK3A (0.30) | GSK3BGSK3APDE11A | |
| SCHEMBL17986919 | 0.78 | PIK3CD (0.31) | GSK3BPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL17657955 | 0.77 | GSK3A (0.37) | GSK3BGSK3AMAT2AGAANPC1 | |
| SCHEMBL17174856 | 0.77 | PIK3CD (0.42) | PIK3CDPIK3R2PIK3CGPIK3R1 | |
| SCHEMBL15549142 | 0.76 | KMT2A (0.38) | GSK3BGSK3AMAT2AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941162-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-10919914-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190330240-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2019-10-31 | — | — | US | disclosed |
| US-20190135833-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| US-10253047-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170369511-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| US-9708348-B2 | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708348-B2 | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160122365-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20150307520-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | HUTCHISON MEDIPHARMA LTD (CN) | 2015-10-29 | — | — | US | disclosed |
| US-20150291593-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LTD (CN) | 2015-10-15 | — | — | US | disclosed |
| US-20150291593-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LTD (CN) | 2015-10-15 | — | — | US | disclosed |
| US-20150291593-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LTD (CN) | 2015-10-15 | — | — | US | disclosed |
| EP-2877472-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITION AND METHODS THEREOF | Hutchison Medipharma Limited (CN) | 2015-06-03 | — | — | EP | disclosed |
| WO-2014015830-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITION AND METHODS THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014015830-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITION AND METHODS THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014015523-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014015523-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014015675-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014015675-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919914-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | GSK3B 92/4885GSK3A 82/4885MAT2A 2283/4885 |
| US-20150307520-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | PIK3C3, PIK3C2B, PIK3C2A | GSK3B 116/4885GSK3A 161/4885MAT2A 2937/4885 |
| US-20170369511-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | GSK3B 92/4885GSK3A 82/4885MAT2A 2283/4885 |
| US-20190135833-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | GSK3B 92/4885GSK3A 82/4885MAT2A 2283/4885 |
| US-20160122365-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | GSK3B 92/4885GSK3A 82/4885MAT2A 2283/4885 |
| US-20150291593-A1 | NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS | PIK3C2B, PIK3C3, PIK3C2A | GSK3B 79/4885GSK3A 119/4885MAT2A 3168/4885 |
| US-10941162-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | GSK3B 121/4885GSK3A 143/4885MAT2A 2211/4885 |
| US-20190330240-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | GSK3B 92/4885GSK3A 82/4885MAT2A 2283/4885 |
| US-10253047-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | GSK3B 101/4885GSK3A 105/4885MAT2A 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.